Comment on Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). [J Clin Oncol. 2017]
Nivolumab in pretreated non-small cell lung cancer: Continuing the immunolution / Salati, Massimiliano; Baldessari, Cinzia; Cerbelli, Bruna; Botticelli, Andrea. - In: TRANSLATIONAL LUNG CANCER RESEARCH. - ISSN 2218-6751. - 7:Suppl 2(2018), pp. S91-S94. [10.21037/tlcr.2018.01.14]
Nivolumab in pretreated non-small cell lung cancer: Continuing the immunolution
Cerbelli, Bruna;Botticelli, Andrea
2018
Abstract
Comment on Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). [J Clin Oncol. 2017]File allegati a questo prodotto
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
